BACKGROUND: The progression of @entity309 ( @entity309 ) can be retarded or halted by disease modifying antirheumatic drugs (DMARDs). Next to inefficacy, @entity137 limits their use. OBJECTIVE: To explore the @entity137 profiles of DMARDs in daily life. @entity1 AND METHODS: Five hundred and ninety three @entity1 with @entity309 charts (>2300 @entity1 years of treatment) were reviewed at two rheumatology outpatient clinics. All recorded data on @entity137 and reasons for stopping treatment were collected. RESULTS: Adverse events were common reasons for treatment discontinuation (42% of treatments). In 70% they were subjectively reported at the clinical visit, while substantial laboratory abnormalities were seen relatively rarely (9% of treatments: abnormal liver function tests in 5%; @entity854 in 3%; @entity8 in 1%). No single case of @entity989 from antimalarial drugs (that is, an incidence of <0.3 events/1000 @entity1 years) was found, although eye examinations by the specialists were abnormal 30 times per 1000 @entity1 years, mostly revealing @entity2372 . Most commonly reported symptoms per 1000 @entity1 years were @entity390 (54 events), @entity490 (37 events), and @entity1910 (34 events). Adverse events were more likely to occur with increasing number of consecutive DMARD courses. CONCLUSION: The first DMARD course in a @entity1 seems to be safer than the consecutive ones. In addition, the incidence of adverse events (AEs) seems to be similar for high and low dose treatment. Data are also provided on types and incidence of AEs that are consistent with previous studies in other countries and different settings.

@entity137 profiles of traditional disease modifying antirheumatic drugs for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity8 :: ('MESH:D007674', 'Disease') :: ['impaired renal function'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity1910 :: ('MESH:D005076', 'Disease') :: ['rashes'] @entity2372 :: ('MESH:C562399', 'Disease') :: ['keratopathy'] @entity854 :: ('MESH:D018376', 'Disease') :: ['haematological abnormalities'] @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain'] @entity989 :: ('MESH:D012164', 'Disease') :: ['retinopathy'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']
@entity309 :: (MESH:D001172,Disease) :: ['rheumatoid arthritis']
